Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer

Guozhen Deng, He Zha, Hongzhi Luo, Zhou YiFrontiers in Bioengineering and Biotechnology 2023 · DOI

Abstract

The increasing global burden of cancer necessitates the development of precise intervention measures for detection and treatment. Current clinical tumor markers and imaging techniques often lack the necessary sensitivity, specificity, or speed for optimal patient outcomes. This review examines the synergy between aptamers—highly specific oligonucleotides—and gold nanoparticles (AuNPs), which offer unique optical properties and biocompatibility. The resulting aptamer-AuNP systems provide a versatile platform for early diagnosis and targeted therapy, characterized by high specificity and reduced side effects.

Introduction: The Precision Oncology Challenge

Cancer remains a leading cause of mortality worldwide, largely due to the limitations of current diagnostic and therapeutic tools. Clinical biomarkers like CEA and CA-125 often exhibit low sensitivity, leading to late-stage detection. While advanced imaging techniques like PET and SPECT offer high sensitivity, they are often time-consuming and cannot provide molecular-level pathological details.

Therapeutically, conventional methods such as surgery, radiotherapy, and chemotherapy are frequently limited by the cancer's stage or the risk of recurrence. Systemic treatments often cause significant damage to healthy tissues, resulting in severe side effects. There is an urgent need for "smart" systems that can distinguish between malignant and healthy cells with high precision.

Methodology: Engineering the Aptamer-AuNP Platform

The integration of aptamers and gold nanoparticles (AuNPs) creates a powerful "theranostic" (therapeutic + diagnostic) tool.

Aptamers: Chemical Antibodies

Aptamers are short, single-stranded DNA or RNA sequences (typically 25–90 nucleotides) identified through the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) process. Unlike traditional protein antibodies, aptamers are synthesized chemically, ensuring high purity and low immunogenicity. Their ability to fold into complex three-dimensional structures allows them to bind to specific biomarkers with high affinity and selectivity.

Gold Nanoparticles (AuNPs): The Versatile Chassis

AuNPs serve as an ideal delivery vehicle due to their high surface-area-to-volume ratio, allowing for dense functionalization with aptamers and drugs. Crucially, they exhibit Surface Plasmon Resonance (SPR), which enables them to scatter light for imaging and convert light energy into heat for localized therapy.

Overview of aptamer-gold nanoparticle systems for cancer diagnosis and therapy, illustrating synthesis, recognition, and various output/treatment modalities.

Key Insights: Mechanisms of Action

The synergy of these technologies allows for several advanced mechanisms:

  • The Theranostic Edge: AuNPs can act as contrast agents for CT scans while simultaneously serving as vehicles for photothermal therapy. Upon irradiation with Near-Infrared (NIR) light, the gold particles generate localized heat to ablate tumor cells.
  • Targeted Accumulation: These systems exploit the Enhanced Permeability and Retention (EPR) effect. Tumors often have "leaky" vasculature and poor lymphatic drainage, allowing nanoparticles to accumulate preferentially in cancerous tissue.
The Enhanced Permeability and Retention (EPR) effect facilitates the passive accumulation of nanoparticles in cancerous tissue compared to the restricted flow in normal tissue.
  • Chemical Robustness: Aptamers are more thermally stable than antibodies and can be easily modified to resist nuclease degradation, extending their half-life in the bloodstream.

Clinical Potential and Results

Research has demonstrated the superior performance of aptamer-AuNP platforms across various cancer types:

  • Prostate Cancer: Biosensors utilizing this technology have achieved a detection limit for Prostate Specific Antigen (PSA) as low as 3.0 pg/mL, significantly outperforming standard clinical assays.
  • Breast Cancer: Dual-aptamer systems targeting ER and HER2 receptors have enabled precise molecular subtyping, which is critical for tailoring personalized treatment strategies.
  • Targeted Drug Delivery: In colorectal cancer models, aptamer-functionalized AuNPs successfully delivered Doxorubicin specifically to malignant cells. This approach reduced cancer cell proliferation more effectively than the free drug while minimizing systemic toxicity.

Future Perspectives and Limitations

Despite the promising results in laboratory and animal models, several hurdles remain for clinical translation:

  1. In Vivo Stability: The complex biological environment can lead to the formation of a "protein corona" around nanoparticles, potentially interfering with aptamer targeting.
  2. Long-term Biocompatibility: While gold is generally considered safe, the long-term metabolic clearance and potential accumulation in the liver and spleen require further investigation.
  3. Manufacturing Scalability: Transitioning from laboratory-scale synthesis to standardized, large-scale pharmaceutical production is a significant industrial challenge.
  4. Clinical Pipeline: The "bench-to-bedside" transition is slow; currently, only a few aptamer-based therapies are in human clinical trials.

Continued research into the molecular interactions and long-term safety of these nanoplatforms will be essential to realizing the full potential of precision oncology.

Summary updated

Abstract

The burden of incidence rate and mortality of cancer is increasing rapidly, and the development of precise intervention measures for cancer detection and treatment will help reduce the burden and pain of cancer. At present, the sensitivity and specificity of tumor markers such as CEA and CA-125 used clinically are low, while PET, SPECT, and other imaging diagnoses with high sensitivity possess shortcomings, including long durations to obtain formal reports and the inability to identify the molecular pathological type of cancer. Cancer surgery is limited by stage and easy to recur. Radiotherapy and chemotherapy often cause damage to normal tissues, leading to evident side effects. Aptamers can selectively and exclusively bind to biomarkers and have, therefore, gained attention as ligands to be targeted for cancer detection and treatment. Gold nanoparticles (AuNPs) are considered as promising nano carriers for cancer diagnosis and treatment due to their strong light scattering characteristics, effective biocompatibility, and easy surface modification with targeted agents. The aptamer-gold nanoparticles targeting delivery system developed herein can combine the advantages of aptamers and gold nanoparticles, and shows excellent targeting, high specificity, low immunogenicity, minor side effects, etc., which builds a bridge for cancer markers to be used in early and efficient diagnosis and precise treatment. In this review, we summarize the latest progress in the application of aptamer-modified gold nanoparticles in cancer targeted diagnosis and delivery of therapeutic agents to cancer cells and emphasize the prospects and challenges of transforming these studies into clinical applications.
BibTeX
@inproceedings{deng2023aptamer,
  author = {Guozhen Deng and He Zha and Hongzhi Luo and Zhou Yi},
  title = {{Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2023},
  doi = {10.3389/fbioe.2023.1118546},
}
Figure